Compare F.N.B. Corporation Common Stock (FNB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs TG Therapeutics Inc — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and F.N.B. Corporation Common Stock pays a 3.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| FNB | TGTX | |
|---|---|---|
Market Cap | $6.07B | $8.32B |
Volume | 5,600,609 | 1,001,204 |
Sector | Financials | Health |
52-Week High | $19.49 | $59.06 |
52-Week Low | $14.65 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $10.61B | $8.52B |
Dividend Yield | 3.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
